EAST PROVIDENCE, R.I. (WPRI) — The U.S. Food and Drug Administration (FDA) has declared a nationwide shortage of an injectable drug that prevents life-threatening allergic reactions.
The FDA said the EpiPen and the EpiPen Jr. are in limited supply due to manufacturing issues and “pharmacy-level supply disruptions.”
The nonprofit organization Food Allergy Research & Education called on the FDA, the Department of Health and Human Services (HHS) and the Trump administration to take immediate action in regards to the shortage.
According to FARE, more than 400 patients in 45 states reported having difficulty in filling prescriptions for Mylan’s devices containing epinephrine since May 2. It’s unclear if Rhode Island or Massachusetts were included in the list.
“I am currently without an epinephrine auto-injector,” one patient said. “I was willing to get ANY auto-injector, but there are NONE. I’m scared that I might go into anaphylaxis and I will die.”
“I was told that in case of allergic reaction to just call 911. My daughter is 11 and has severe peanut and tree nut allergies,” another patient said.
Mylan told the FDA a few months ago the drug was in short supply due to manufacturing delays.
FARE suggested patients who are having difficulty finding the EpiPen of their choice due to the shortage should speak to their physicians about obtaining a description for a different auto-injector.